New Report: Global Veterinary Drugs Market Size (2025–2034)

The global veterinary drugs market was valued at US$30.54 billion in 2025 and is projected to reach US$53.05 billion by 2034, expanding at a 6.44% CAGR (2026–2034). Growth is underpinned by intensifying disease-prevention spending, rising pet-healthcare outlays, and regulatory support for new and conditionally approved animal drugs. South America is highlighted for strong demand across cattle, poultry, and swine, while North America remains the largest regional market and Asia Pacific records the strongest growth trajectory.

Market Size, Forecast, and Key Assumptions

Source: Maximize Market Research, Sept 22, 2026

Growth Drivers

1) Rising zoonotic and production-disease risk

• 47% of animal diseases with available information have zoonotic potential, per WOAH—pushing governments, producers, and pet owners toward prevention and early treatment

• Outbreaks of avian influenza in mammals more than doubled in 2024 vs 2023, amplifying biosecurity and therapeutic demand at the wildlife–livestock–companion interface

2) Pet humanization and healthcare spend

• Companion-animal owners are prioritizing preventive care, chronic-disease management, and specialty therapies (e.g., monoclonal antibodies for canine atopic dermatitis)

• Long-acting and convenience-focused products (e.g., 12‑month flea/tick control) are gaining share as owners and practices seek adherence and fewer visits

3) Livestock intensification and food-security agendas

• Large livestock populations in Asia Pacific and export-oriented production in South America sustain demand for vaccines, anti-infectives, parasiticides, and metabolic/reproductive health products

• National programs (e.g., One Health, antimicrobial stewardship) are shifting spend toward prevention, diagnostics, and alternatives to antibiotics

4) Regulatory tailwinds and pipeline activity

• The FDA CVM Green Book and ongoing approvals (NADAs/ANADAs/CNADAs) encourage portfolio expansion across species and indications

• Recent U.S. actions include: MUMS Blueprint 2026–2028 (minor species/uncommon diseases), GFI #152 (antimicrobial-resistance risk evaluation), and multiple emergency/conditional authorizations for New World screwworm treatments

Restraints and Headwinds

• Stringent approval and compliance requirements (safety, efficacy, manufacturing, labeling, food safety) extend timelines and raise costs, especially for smaller entrants

• Antimicrobial resistance (AMR) stewardship: WOAH data (covering 71% of global animal biomass) show a 5% decline in antimicrobial use per kg of animal biomass from 2020 to 2022 (102 mg → 97 mg), pressuring traditional antibiotic volumes and pushing R&D toward vaccines, alternatives, and targeted therapies

Segmentation Overview

By Product

• Anti-infectives

• Anti-inflammatory drugs

• Parasiticides

• Others (e.g., anesthetics, sedatives, metabolic/reproductive health, oncology, dermatology)

Demand is rising for long-acting formulations, combination products, and species-specific therapies

By Animal

• Companion animals (dogs, cats, others)

• Livestock (cattle, poultry, swine, small ruminants, aquaculture)

• Others (equine, minor species)

Companion-animal spend is a primary growth engine; livestock remains the volume base

By Route of Administration

• Oral

• Injectable

• Topical

• Others (e.g., implants, pour-on, intra-mammary, intra-articular)

Long-acting injectables and extended-release topicals are expanding share in companion and livestock segments

By Distribution Channel

• Veterinary clinics and hospitals

• Retail/veterinary pharmacies

• E-commerce platforms

• Others (distributors, institutional tenders)

E-commerce is growing for companion-animal parasiticides and chronic therapies; clinics remain dominant for prescription and biologic products

Regional Landscape

North America (largest share)

• Supported by high pet-healthcare spend, advanced veterinary infrastructure, large-scale livestock production, and strong pharma R&D

• United States leads; Canada and Mexico contribute via established services and livestock health demand

• Recent regulatory activity (e.g., screwworm EUAs/authorizations, MUMS, GFI #152) directly shapes product strategy

Europe (mature, regulation-led)

• Preventive healthcare, developed veterinary services, and strict animal-health regulations underpin demand

• In 2025, the EMA recommended 30 veterinary medicines for marketing authorization—evidence of continued pipeline activity

• Key markets: Germany, UK, France, Italy, Spain

Asia Pacific (fastest growth)

• Growth drivers: large livestock populations, rising pet ownership, expanding aquaculture, and improving veterinary infrastructure

• China and India are major markets; Japan, South Korea, Australia also contribute

• Policy emphasis on One Health, disease control, and feed/health integration supports sustained

Middle East & Africa

• Supported by livestock healthcare investment, poultry/dairy production, food-security programs, and veterinary infrastructure build-out

• Important markets: Saudi Arabia, UAE, South Africa, Egypt, Israel

South America (strong demand in cattle, poultry, swine)

• Brazil leads regional demand; Argentina, Chile, Colombia, Peru contribute via livestock, poultry, aquaculture, and companion-animal healthcare

• Extensive cattle systems and integrated poultry/swine value chains drive parasiticide, vaccine, and anti-infective consumption

Competitive Landscape

The market is highly competitive, with competition centered on new product launches, regulatory approvals, M&A, biotechnology development, generics, and geographic expansion

Leading Players (illustrative)

• Zoetis Services LLC

• Boehringer Ingelheim International GmbH

• Merck & Co., Inc. (MSD Animal Health)

• Elanco Animal Health Inc.

• Dechra Pharmaceuticals PLC

• Ceva Santé Animale

• Virbac S.A.

• Vetoquinol S.A.

• Bimeda

• Biogénesis Bagó

• Phibro Animal Health Corporation

• Norbrook Laboratories

• HIPRA, Huvepharma, Kyoritsu Seiyaku, Troy Laboratories, Jurox, Vivaldis, VetViva, Richter GmbH, Vetiquinol, WuXi Biologics, Mediwin Laboratories, Vetnation Pharma, Vee Remedies, among others

Company Spotlight: Zoetis

• 2025 revenue: US$9.47 billion; operations in 100+ countries; ~300 product lines across parasiticides, vaccines, anti-infectives, pain management, and more

• August 2026: Received FDA Emergency Use Authorization for Simparica Trio to treat New World screwworm in dogs/puppies—illustrating rapid repurposing of established assets against emerging threats

Recent Regulatory and Product Developments (2026)

Strategic Implications for Industry Stakeholders

For Veterinary Pharmaceutical Companies

• Prioritize long-acting and specialty modalities (e.g., mAbs, extended-release injectables) in companion animals to capture willingness-to-pay and adherence value

• Diversify beyond antibiotics: invest in vaccines, parasiticides, immunomodulators, and gut-health solutions aligned with AMR stewardship and WOAH/FAO One Health priorities

• Leverage conditional/emergency pathways (CNADAs, EUAs) for emerging diseases (e.g., screwworm) while building real-world evidence for full approvals

For Livestock Integrators and Feed/Health Suppliers

• In South America and Asia Pacific, align health programs with biosecurity, vaccination calendars, and parasite control to protect export eligibility and productivity

• Use diagnostics-driven health plans to optimize antimicrobial use and meet buyer/regulatory expectations on residue and AMR

For Distributors and Retail/E‑commerce Channels

• Expand subscription and adherence programs for chronic companion-animal therapies and year-round parasiticides; integrate tele-triage and clinic partnerships to protect Rx integrity

• In emerging markets, build cold-chain and last-mile capabilities for biologics and temperature-sensitive products as livestock and pet segments grow